Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754691 | 0.90 | NPC1 (0.41) | CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL25754752 | 0.88 | SMN1; SMN2 (0.38) | CYP1A2MAPK1SMN1; SMN2PAOXHRH3 | |
| SCHEMBL25754697 | 0.87 | RAD52 (0.40) | CYP1A2MAPK1SMN1; SMN2PAOXRAD52 | |
| SCHEMBL25754758 | 0.85 | HRH3 (0.39) | CYP1A2MAPK1SMN1; SMN2HRH3MAPT | |
| SCHEMBL25754592 | 0.83 | ALDH1A1 (0.50) | CYP1A2MAPK1SMN1; SMN2PAOXHRH3 | |
| SCHEMBL25754754 | 0.80 | KMT2A (0.36) | CYP1A2MAPK1SMN1; SMN2HRH3MAPT | |
| SCHEMBL25754613 | 0.76 | HRH3 (0.42) | CYP1A2MAPK1SMN1; SMN2HRH3MAPT | |
| SCHEMBL25754731 | 0.76 | KDM4E (0.39) | CYP1A2MAPK1SMN1; SMN2RAD52HRH3 | |
| SCHEMBL25754653 | 0.74 | HRH3 (0.45) | CYP1A2MAPK1SMN1; SMN2PAOXRAD52 | |
| SCHEMBL25754655 | 0.74 | HRH3 (0.45) | CYP1A2MAPK1SMN1; SMN2PAOXRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CYP1A2 3367/4885MAPK1 3542/4885SMN1; SMN2 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.